UIC-2018-001 – Novel, First-in-class therapeutic strategy for asthma treatment

300 million people worldwide suffer from asthma, with 60 million cases in the United States. There are a staggering 180,000 annual asthma-related deaths worldwide. The annual direct cost of asthma treatment is approximately 50 billion USD, and the asthma prescription drug market was 30 billion USD in 2016. The economic impact of asthma are estimated to exceed those of TB and HIV/AIDS combined. The current standard of care is inhaled corticosteroids. However, the treatment targets symptoms and is not effective in ~10% of patients. Alternative treatments include injectable, anti-body based biologics, but such solutions are costly. UIC Solution Researchers in the UIC College of Medicine propose the use of inhalable CSF1R inhibitor (pexidartinib) for the treatment asthma. CSF1R has been shown to be involved in the dendritic cell immune response to allergens (Moon HG, et al. 2018). Treatment with CSF1R inhibitor treats the cause of an asthmatic episode at the source. Pexidartinib is involved in numerous phase II/III studies which have demonstrated a lack of toxicity and adverse reactions at concentrations far above the concentration required for asthma indication. Inhibition of CSF1R could be a safer alternative to injectable biologics for individuals who do not respond to standard corticosteroids. Nelson Grihalde grihalde@otm.uic.edu 312-996-4129

Related Blog

Smart, interactive desk

Get ready to take your space management game to the next level with the University of Glasgow’s innovative project! By combining the

Mechanical Hamstring™

University of Delaware Technology Overview This device was created to allow athletes who suffer a hamstring strain to return to the field

Join Our Newsletter

                                                   Receive Innovation Updates, New Listing Highlights And More